Cost burden of severe community-acquired rotavirus gastroenteritis requiring hospitalization in the Czech Republic, Slovakia, Poland and Hungary: a retrospective patient chart review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F16%3A10329446" target="_blank" >RIV/00216208:11140/16:10329446 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S2212109916300115" target="_blank" >http://www.sciencedirect.com/science/article/pii/S2212109916300115</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.vhri.2016.07.005" target="_blank" >10.1016/j.vhri.2016.07.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cost burden of severe community-acquired rotavirus gastroenteritis requiring hospitalization in the Czech Republic, Slovakia, Poland and Hungary: a retrospective patient chart review

Popis výsledku v původním jazyce

To provide valuable local data on the economic burden of rotavirus gastroenteritis (RVGE) for decision making on introduction of rotavirus vaccination in Central European countries. We conducted a retrospective patient hospital chart review during the winter RVGE peak in the Czech Republic (n = 109), Hungary (n = 109), Poland, (n = 112), and Slovakia (n = 115) to estimate resource use and associated costs from the payer's perspective in children younger than 5 years with severe RVGE requiring hospitalization. Microcosting analysis was used to estimate the average costs of treating RVGE inpatients including pre- and posthospitalization costs. The average cost of treatment was EUR476, EUR316, EUR741, and EUR594 in the Czech Republic, Hungary, Poland, and Slovakia, respectively. Extrapolating these costs to the total number of RVGE hospitalizations gives annual cost estimates of EUR2.1 million, EUR1.5 million, EUR13.2 million, and EUR1.5 million, respectively. The main component of expenditure in all the four countries is the hospital stay, but wide variation among countries was observed (total cost of treating RVGE in hospital was almost 2.5-fold higher in Poland than in Hungary). In countries with diagnosis related group (DRG) costs available, the best agreement between real resource-use-driven costs and the DRG cost was found in the Czech Republic and Hungary, with differences of only EUR22 and EUR33, respectively. In Poland, the microcosting indicated higher overall costs incurred in hospital than the DRG cost, with a difference exceeding EUR190. Hospitalization of children with RVGE represents a substantial economic burden for the national health systems in these countries.

Název v anglickém jazyce

Cost burden of severe community-acquired rotavirus gastroenteritis requiring hospitalization in the Czech Republic, Slovakia, Poland and Hungary: a retrospective patient chart review

Popis výsledku anglicky

To provide valuable local data on the economic burden of rotavirus gastroenteritis (RVGE) for decision making on introduction of rotavirus vaccination in Central European countries. We conducted a retrospective patient hospital chart review during the winter RVGE peak in the Czech Republic (n = 109), Hungary (n = 109), Poland, (n = 112), and Slovakia (n = 115) to estimate resource use and associated costs from the payer's perspective in children younger than 5 years with severe RVGE requiring hospitalization. Microcosting analysis was used to estimate the average costs of treating RVGE inpatients including pre- and posthospitalization costs. The average cost of treatment was EUR476, EUR316, EUR741, and EUR594 in the Czech Republic, Hungary, Poland, and Slovakia, respectively. Extrapolating these costs to the total number of RVGE hospitalizations gives annual cost estimates of EUR2.1 million, EUR1.5 million, EUR13.2 million, and EUR1.5 million, respectively. The main component of expenditure in all the four countries is the hospital stay, but wide variation among countries was observed (total cost of treating RVGE in hospital was almost 2.5-fold higher in Poland than in Hungary). In countries with diagnosis related group (DRG) costs available, the best agreement between real resource-use-driven costs and the DRG cost was found in the Czech Republic and Hungary, with differences of only EUR22 and EUR33, respectively. In Poland, the microcosting indicated higher overall costs incurred in hospital than the DRG cost, with a difference exceeding EUR190. Hospitalization of children with RVGE represents a substantial economic burden for the national health systems in these countries.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Value in Health Regional Issues

ISSN

2212-1099

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

September

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

53-60

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-84986893077